Immunomic Announces Scientific Advisory Board Additions

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board.

“We could not be more pleased to have in place a Scientific Advisory Board with such exceptional and varied experience in the field of immunotherapy and the life sciences,” stated Immunomic CEO, Dr. William Hearl. “Our new additions ensure the LAMP-Vax technology platform is poised for success as we continue to apply the DNA vaccine in oncology.”

Back to news